SES104a - Gene Therapy Drug Product Manufacture Challenges and Opportunities

This presentation will focus on how Thermo Fisher Scientific and Optima Pharma have developed innovative solutions to address the unique challenges facing gene therapy drug product manufacturing.

Thermo Fisher and Optima Pharma have partnered to leverage each's experience and expertise to design and deliver two specialized fill finish lines as part of Thermo Fisher Scientific's new, state of the art viral vector manufacturing site in Plainville, MA. This 288,000 SF facility, which is now operational, offers end-to-end viral vector and gene therapy capabilities to meet the rapidly growing and maturing needs of the gene therapy industry. Case studies of how specific challenges have been addressed via technology, equipment and single use design will be presented alongside potential new technologies that are emerging in our industry.